BAMF
TVTX icon

BI Asset Management Fondsmaeglerselskab’s Travere Therapeutics TVTX Stock Holding History

BI Asset Management Fondsmaeglerselskab’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,448
Closed -$26K – 909
2025
Q1 		$26K Buy
+1,448
New +$29.4K ﹤0.01% 895

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BI Asset Management Fondsmaeglerselskab's TVTX Position: Q2 2025 in Review

BI Asset Management Fondsmaeglerselskab sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 1,448 shares — an estimated $26K sold.

BI Asset Management Fondsmaeglerselskab first reported a position in TVTX in Q1 2025 and held it in 1 quarter. The position peaked at $26K in Q1 2025. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • BI Asset Management Fondsmaeglerselskab reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • BI Asset Management Fondsmaeglerselskab sold 1,448 Travere Therapeutics shares in Q2 2025, an estimated $26K.
  • BI Asset Management Fondsmaeglerselskab first reported a position in Travere Therapeutics in Q1 2025 and held it in 1 quarter.
  • BI Asset Management Fondsmaeglerselskab's Travere Therapeutics position peaked at $26K in Q1 2025.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on BI Asset Management Fondsmaeglerselskab's 13F filing for Q2 2025, filed 14 Aug 2025.